The study concluded that ipilimumab, either alone or in combination with the gp100 peptide vaccine, significantly improved overall survival in patients with previously treated metastatic melanoma compared to treatment with gp100 vaccine alone. The gene discussed is PMEL; the disease is metastatic melanoma.